Mounjaro KwikPen 15mg: reaching the highest dose

Is 15mg the automatic next step once you hit 12.5mg?

Not automatically. The titration schedule exists because each increase brings a new adjustment period for your body. A prescriber reviewing your case before a dose increase will look at two things above all: how well you tolerated the previous dose, and whether your weight trajectory is still moving. If nausea or other gastrointestinal symptoms were significant at 12.5mg and have not settled, most prescribers will hold the dose rather than push higher. If tolerance was fine but weight loss has plateaued, moving to 15mg becomes a more straightforward conversation.

It also matters that you have genuinely been taking the 12.5mg dose as intended. A quick habit worth building before any review: check the dose window on each pen before you inject to confirm the strength matches what your prescription says. It takes less than ten seconds and catches the occasional dispensing mix-up before it affects your results or your review. If you want to check exactly what the earlier strengths look like, the Mounjaro KwikPen 5mg page and the Mounjaro KwikPen 10mg page show the pens in detail, which can help you spot a mismatch in a fridge at a glance, and the Mounjaro KwikPen 7.5mg page covers that intermediate strength if you need a reference point for what that pen looks like too.

At nume, sorry. At the nume, let us be precise: at nume, every dose increase is assessed by a GPhC-registered prescriber before we supply the next strength. We ask for evidence that the current dose has been taken and tolerated; this protects you from moving up too fast, which is one of the most common triggers for side effects that send people off treatment entirely.

What the 15mg evidence actually tells you

The SURMOUNT-1 trial, published in the New England Journal of Medicine, randomised 2,539 adults with obesity but without type 2 diabetes. Those assigned to tirzepatide 15mg achieved an average weight reduction of around 20–21% at 72 weeks, compared with roughly 3% in the placebo group. Those are average figures: some participants lost more, others less. A trial average is a starting point for expectation-setting, not a personal forecast.

NICE's appraisal of tirzepatide, TA1026, notes that if a patient has not achieved at least 5% weight loss after six months at the highest tolerated dose, continuing treatment should be reviewed. That review point applies at 15mg just as it does at any other strength. Reaching the maximum dose does not reset the clinical clock, it starts a fresh period of assessment against outcomes. For broader context on the full Mounjaro treatment journey, the Mounjaro overview page covers the licensed purpose and eligibility picture in one place.

It is also worth knowing that 15mg is only licensed as part of a programme that includes a reduced-calorie diet and increased physical activity. The medicine and the lifestyle changes work together; the trial evidence was generated under those combined conditions.

Side effects that can be more pronounced at higher doses

Gastrointestinal effects (nausea, loose stools, reflux, occasional vomiting) are the most frequently reported. They tend to be most noticeable in the first two to three weeks after an increase and usually settle, though 'usually' does real work in that sentence: a minority of people find them persistent enough to step back down. At 15mg, the gut-slowing effect of tirzepatide is at its most pronounced, which is part of how the medicine reduces appetite but is also why some people feel very full or have slow digestion even with small meals.

The NHS tirzepatide medicines page lists the full side-effect profile with guidance on which symptoms to treat at home and which warrant a call to your prescriber or, urgently, 111. Severe and persistent stomach pain that radiates to the back should be treated as urgent, it is the symptom pattern associated with pancreatitis, which the MHRA flagged as an infrequent but serious risk across GLP-1 medicines. The nume FAQs address common side-effect questions in more detail. Any side effect you are unsure about during treatment can be raised through our aftercare team, available seven days a week.

Private access versus NHS access at this dose

On the NHS, tirzepatide is being rolled out in phases under NICE TA1026. The current eligibility criteria are strict (BMI thresholds and a requirement to have several qualifying conditions) and most patients who reach 15mg through an NHS route do so within a specialist service. The typical dosing pathway page explains how the NHS titration timeline tends to work in practice.

Through a regulated private pharmacy, the route is more direct: clinical assessment, prescriber review, and (if suitable) supply of the appropriate strength, including 15mg for patients who are already established on treatment. Cost is a real consideration at this dose. Private pricing for higher-strength tirzepatide pens reflects both the list price and the clinical service around it. The cost context page is honest about what private treatment typically costs and what transparent pricing should include. Eli Lilly revised UK list prices from September 2025, and the 15mg pen sits at the top of that revised schedule.

If you are already on tirzepatide elsewhere and considering transferring, starting a free consultation with nume is how that process begins. Our prescribers review evidence of your current dose before any supply.